PD-404182 (PD 404182; PD404182) is a novel and potent inhibitor of KDO 8-P synthase with antiangiogenic and antiviral activity (anti-HIV and anti-herpes simplex virus). It inhibits KDO 8-P synthase with a Ki of 26 nM. It is effective against gram negative bacteria.
Physicochemical Properties
| Molecular Formula | C11H11N3S |
| Molecular Weight | 217.29 |
| Exact Mass | 217.067 |
| CAS # | 72596-74-8 |
| PubChem CID | 6603967 |
| Appearance | Light yellow to yellow solid powder |
| LogP | 1.022 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Heavy Atom Count | 15 |
| Complexity | 313 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C1=CC=C2C(=C1)C3=NCCCN3C(=N)S2 |
| InChi Key | JNENSSREQFBZGT-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C11H11N3S/c12-11-14-7-3-6-13-10(14)8-4-1-2-5-9(8)15-11/h1-2,4-5,12H,3,6-7H2 |
| Chemical Name | 3,4-dihydro-2H,6H-benzo[e]pyrimido[1,2-c][1,3]thiazin-6-imine |
| Synonyms | PD404182 PD 404182 PD-404182 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Asymmetric dimethylarginine (ADMA) in EC is increased by around 70% in response to PD 404182 (20 μM) [1]. In vitro, PD 404182 (50-100 μM; 18 hours) reduces endothelial tube formation without compromising the integrity of cell membranes or causing cytotoxicity [1]. With an IC50 of 1 μM, PD 404182 suppresses HIV-1 in seminal plasma[2]. When applied to various human cell lines, freshly activated PBMCs, primary CD4+ T lymphocytes, macrophages, dendritic cells, and lactobacilli in the normal vaginal flora, PD 404182 (300 μM; 30 min) shows minimal toxicity [2]. |
| Cell Assay |
Cell viability assay [1] Cell Types: Human dermal microvascular endothelial cells (EC) Tested Concentrations: 10-300 μM Incubation Duration: 24 hrs (hours) Experimental Results: No cytotoxicity is induced. |
| References |
[1]. Ghebremariam YT, et, al. A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide. J Pharmacol Exp Ther. 2014 Jan; 348(1): 69-76. [2]. Chamoun-Emanuelli AM, et, al. Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide. Antimicrob Agents Chemother. 2014; 58(2): 687-97. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~50 mg/mL (~230.11 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (11.51 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (11.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6021 mL | 23.0107 mL | 46.0214 mL | |
| 5 mM | 0.9204 mL | 4.6021 mL | 9.2043 mL | |
| 10 mM | 0.4602 mL | 2.3011 mL | 4.6021 mL |